JNJ-A07

**JNJ-A07** is a highly potent, orally active **small molecule** antiviral agent developed by Janssen (Johnson & Johnson) as a pan-serotype, pan-genotype inhibitor of dengue virus (DENV). It targets the protein-protein interaction between the viral non-structural proteins **NS4A-2K-NS4B** (a cleavage intermediate of NS4B precursor) and the **NS2B/NS3 protease/helicase complex**, preventing de novo biogenesis of vesicle packets (VPs) essential for DENV RNA replication without affecting established VPs or polyprotein cleavage. JNJ-A07 demonstrates picomolar to nanomolar EC50 values across DENV serotypes in cell-based assays, efficacy in mouse models, and activity in mosquito cells and ex vivo/live Aedes aegypti models by blocking viral transmission when ingested via blood meal; it completed first-in-human trials with good safety and tolerability, though a related compound (JNJ-1802/JNJ-64281802) advanced to clinical prophylaxis studies.[1][2][3][6][7]